At present, the clinical associations of high CD163+ TAMs infiltration with poor clinical outcomes had been widely shown in numerous human cancers [37, 38], however, whether CD163+ TAMs, especially infiltrated in invasive front, contribute to better or poorer prognosis still remains contradictory in terms of CRC [39, 40]. The gene discussed is CD163; the disease is cancer.